Conclusion: Collectively, our findings present the rationale for targeting multiple inhibitory pathways including PD-1, Tim-3 and TIGIT to better counteract melanoma-induced cell dysfunction and improve melanoma patients ‘clinical outcome. Here, HAVCR2 is linked to melanoma.